基于介孔二氧化硅纳米颗粒的可控释放体系

基于介孔二氧化硅的控制释放体系具有良好的生物相容性、细胞靶向性、精准响应性控制释放和到达目标位点前有效阻止药物释放等功能特性。近年来,基于介孔二氧化硅的可控释放体系已成为众多科研工作者研究的热点。本文讨论了基于介孔二氧化硅纳米颗粒可控释放体系的特点,同时以不同的响应特性为主线,系统分析和总结了各种响应性介孔二氧化硅控释体系的开关及其控制释放机制,包括氧化还原控释系统、光控释系统、pH控释系统及生物分子相关控释系统等一系列基于介孔二氧化硅的控释系统,并对该领域未来的发展方向作了展望。     

原位限域生长策略制备有序介孔碳负载的超小MoO3纳米颗粒

采用原位限域生长策略制备了一系列有序介孔碳负载的超小MoO₃纳米颗粒复合物(OMC-US-MoO₃). 其中, 有序介孔碳被用作基质来原位限域MoO₃纳米晶的生长. 依此方法制备的MoO₃纳米晶具有超小的晶粒尺寸(<5 nm), 并在介孔碳骨架内具有良好的分散度. 制得的OMC-US-MoO₃复合物具有可调的比表面积(428~796 m²/g)、 孔容(0.27~0.62 cm³/g)、 MoO₃质量分数(4%~27%)和孔径(4.6~5.7 nm). 当MoO₃纳米晶的质量分数为7%时, 所得样品OMC-US-MoO₃-7具有最大的孔径、 最小的孔壁厚度和最规整的介观结构. 该样品作为催化剂时, 表现出优异的环辛烯选择性氧化性能.     

pH响应的介孔二氧化硅纳米颗粒的制备及可控释放

选择带负电荷且溶解度和分子结构对pH值非常敏感的聚丙烯酸作为封堵分子, 采用静电吸附的修饰方法, 制备了pH响应的MCM-41型介孔二氧化硅纳米颗粒. 利用高倍透射电子显微镜(TEM)、 X射线衍射(XRD)、 傅里叶变换红外光谱(FTIR)及比表面积分析等手段表征了介孔二氧化硅纳米颗粒的物理化学性质. 以联钌吡啶染料分子作为模式客体分子, 研究了pH调控下的模式客体分子在介孔二氧化硅纳米颗粒中的包裹及释放行为. 结果表明, 该介孔二氧化硅纳米颗粒对pH具有很好的响应性; 在近中性条件下, 带正电的二氧化硅纳米颗粒通过静电吸附作用吸附带负电的聚丙烯酸, 导致介孔封堵, 使包载的染料分子几乎无释放; 客体分子的释放率随着pH值的降低而升高, 当pH≤5时, 染料分子显著释放, pH=1时客体分子的释放率高达98％, 可以实现对包载客体分子的控制释放. 该pH响应的介孔二氧化硅纳米颗粒载体具有制备简便、 价格低廉和包载量大等优点, 有望应用于药物的控制释放.     

介孔二氧化硅纳米粒子应用于可控药物传输系统的若干新进展

通过对介孔二氧化硅纳米粒子(MSN)载药机理、药物控释机理和靶向方法的介绍,对MSN在可控药物传输系统中的应用加以综述.     

辅以时滞的pH-敏感介孔膦酸锆对双氯芬酸钠的可控结肠靶向释放

以pH-敏感介孔膦酸锆作为药物载体, 选用治疗时辰节律性疾病(风湿性关节炎)的药物双氯芬酸钠作为药物模型, 利用蘸涂的方法对载药的pH-敏感介孔膦酸锆进行时滞膜的包覆, 建立起一个时滞型和pH-敏感型相结合的口服结肠靶向给药系统. 在系统研究pH-敏感介孔膦酸锆对双氯芬酸钠吸附和释放的基础之上, 通过调控时滞膜的厚度控制释放双氯芬酸钠的时滞时间约为6 h. 该给药系统在人工模拟胃液中3 h内完全不释放双氯芬酸钠, 而在人工模拟肠液中最初的3 h(可以看成发生在小肠)所释放的双氯芬酸钠仅为全部释放量的9%, 在之后的46 h内(可以看成发生在结肠)缓慢释放的双氯芬酸钠则占全部释放量的90%以上. 这样, pH-敏感介孔膦酸锆作为新型药物载体与时滞效应相结合, 通过时滞和pH-敏感双重控制实现了治疗时辰节律性疾病药物在结肠的定位释放.     

巯丙基功能化介孔纳米二氧化硅的合成

用三种不同的方法将巯基丙基三甲氧基硅烷(MPTMS)引入二氧化硅网络中, 合成了粒径为50-200 nm的巯丙基功能化的介孔纳米二氧化硅, 并利用透射电子显微镜, 热重分析等手段对其形貌与性能进行了表征. 在巯丙基官能团的作用下介孔纳米二氧化硅的形貌发生了重大改变, 由非常规则的六角形变为纳米棒. 控制反应时间可以调节介孔纳米二氧化硅的粒径大小, 用三乙醇胺代替氢氧化钠可以合成直径在100 nm以下的功能化介孔二氧化硅粒子. 为了保护巯基官能团, 选用了酸醇提取法去除模板. 另外, 对介孔二氧化硅粒子的形成机制也进行了探讨.     

新型负载碳点的介孔有机硅纳米粒子的制备与研究

本文将介孔有机二氧化硅纳米颗粒(MONs)与碳点(CDs)结合,制备新型负载碳点的介孔有机硅纳米粒子(CD@MONs).结果表明成功制备出负载碳点的介孔有机硅复合纳米粒子,详细表征显示产物呈球形,分散性较好,直径为40～60 nm,大小较为均一,孔道大,产物在415 nm激发下,荧光发射波长为670 nm,该复合材料既...     

具有可控分散性的不同粒径氨基酸双功能化介孔二氧化硅纳米颗粒

通过表面活性剂,共结构导向剂（CSDAs）和硅源的自组装合成了具有分散性的不同粒径氨基酸双功能化介孔二氧化硅纳米颗粒. 通过表面活性剂头部与带相反电荷的CSDAs之间的静电相互作用使氨基和羧基基团均匀排列在介孔孔道表面. 通过调节助溶剂或分散剂的加入量来控制颗粒粒径,调节合成溶液pH改变纳米颗粒表面羧基和氨基基团的电荷切换性及其量来控制颗粒的分散性.     

孔径可控的介孔TiO2纳米球的溶剂热合成

以具有微孔结构的乙二醇钛(TG)为前驱体, 采用无模板法制备了一系列单分散的介孔TiO2纳米球. 通过溶剂热处理, 微孔前驱体TG原位水解直接转化为具有介孔结构的TiO2纳米球. 通过X射线粉末衍射(XRD)、扫描电子显微镜(SEM)、透射电子显微镜(TEM)、傅里叶变换红外光谱(FTIR)及氮气吸附-脱附等对产物进行了表征. 测试结果表明, 产物具有高结晶性、均一的形貌、可调的孔径和比表面积.     

介孔碳纳米材料的制备与改性

介孔碳纳米材料因具有快速传输通道、优异的导电性、极高的比表面积和出色的化学稳定性在众多领域受到广泛关注.实现介孔碳纳米材料的可控制备和精准改性是当前的研究热点和重点.基于此,本文分析总结了这类材料的制备和改性方法,并讨论了存在的问题和未来研究方向.     

Lysinated Multiwalled Carbon Nanotubes with Carbohydrate Ligands as an Effective Nanocarrier for Targeted Doxorubicin Delivery to Breast Cancer Cells

Multiwalled carbon nanotubes (MWCNTs) are elongated, hollow cylindrical nanotubes made of sp2 carbon. MWCNTs have attracted significant attention in the area of drug delivery due to their high drug-loading capacity and large surface area. Furthermore, they can be linked to bioactive ligands molecules via covalent and noncovalent bonds that allow for the targeted delivery of anticancer drugs such as doxorubicin. The majority of methodologies reported for the functionalization of MWCNTs for drug delivery are quite complex and use expensive linkers and ligands. In the present study, we report a simple, cost-effective approach for functionalizing MWCNTs with the carbohydrate ligands, galactose (GA), mannose (MA) and lactose (LA), using lysine as a linker. The doxorubicin (Dox)-loaded functionalized MWCNTs were characterized using FT-IR, NMR, Raman, XRD and FE-SEM. The drug–loaded MWCNTs were evaluated for drug loading, drug release and cell toxicity in vitro, in breast cancer cells. The results indicated that the carbohydrate-modified lysinated MWCNTs had greater Dox loading capacity, compared to carboxylated MWCNTs (COOHMWCNTs) and lysinated MWCNTs (LyMWCNTs). In vitro drug release experiments indicated that the carbohydrate functionalized LyMWCNTs had higher Dox release at pH 5.0, compared to the physiological pH of 7.4, over 120 h, indicating that they are suitable candidates for targeting the tumor microenvironment as a result of their sustained release profile of Dox. Doxorubicin-loaded galactosylated MWCNTs (Dox-GAMWCNTs) and doxorubicin loaded mannosylated MWCNTs (Dox-MAMWCNTs) had greater anticancer efficacy and cellular uptake, compared to doxorubicin–loaded lactosylated MWCNTs (Dox-LAMWCNTs) and pure Dox, in MDA-MB231 and MCF7 breast cancer cells. However, neither the ligand conjugated multiwall blank carbon nanotubes (GAMWCNTs, MAMWCNTs and LAMWCNTs) nor the lysinated multiwalled blank carbon nanotubes produced significant toxicity in the normal cells. Our results suggest that sugar-tethered multiwalled carbon nanotubes, especially the galactosylated (Dox-GAMWCNTs) and mannosylated (Dox-MAMWCNTs) formulations, may be used to improve the targeted delivery of anticancer drugs to breast cancer cells.     

Anions as Triggers in Controlled Release Protocols from Mesoporous Silica Nanoparticles Functionalized with Macrocyclic Copper(II) Complexes

Three different mesoporous silica nano‐sized materials ( SC1 , SC2 , and SC3 ), loaded with [Ru(bipy)₃]²⁺ dye (bipy=bipyridine) and functionalized on the external surface with three macrocyclic copper(II) complexes ( C1 , C2 , and C3 ), were synthesized and characterized. When SC1 , SC2 , and SC3 were suspended in water, the entrapped [Ru(bipy)₃]²⁺ dye was free to diffuse from the inner pores to the solution. However, addition of anions induced certain degrees of pore blockage, with subsequent dye release inhibition. Small monovalent and divalent anions were unable to induce complete pore blockage, whereas bulky and highly charged anions induced marked reductions in [Ru(bipy)₃]²⁺ delivery. The best [Ru(bipy)₃]²⁺ delivery inhibitors were ATP and hexametaphosphate anions. Inhibition was ascribed to the interaction of the anions with the grafted Cu^II complexes on the surface of the SC1 , SC2 , and SC3 supports. The hexametaphosphate anion was selected to prepare two capped materials ( SC1‐mPh and SC3‐mPh ). Studies of the [Ru(bipy)₃]²⁺ dye release from solids SC1‐mPh and SC3‐mPh alone and in the presence of a collection of selected anions (HS^?, F^?, Br^?, Cl^?, I^?, CN^?, HPO₄^2?, AcO^?, citrate, NO₃^2?, HCO₃^?, SO₄^2?, and S₂O₈^2?), amino acids (alanine and histidine), thiol‐containing biomolecules (cysteine, methylcysteine, homocysteine, and glutathione (GSH)), and oxidants (H₂O₂) were performed. None of the chemicals tested, except hydrogen sulphide, was able to induce remarkable cargo delivery in both solids. The observed dye release was ascribed to a demetalation reaction of the C1 and C3 complexes induced by the hydrogen sulphide anion.     

中空介孔硅球原位接枝聚苯胺及其pH响应性药物控制释放行为

通过原位化学氧化聚合的方法,在中空介孔二氧化硅纳米粒子表面成功接枝上了聚苯胺(HMSsPANI).借助透射电镜(TEM)、红外光谱(FTIR)、紫外可见吸收光谱(UV-Vis)、氮气脱附吸附等温测试(BET)、热失重(TGA)、小角粉末衍射(XRD)和zeta电位测试等手段表征了其结构性质.通过循环伏安曲线研究,发现HMSs-PANI分散体系在不同pH条件下具有电化学活性的转变性质,证实了HMSs-PANI在酸性条件下能够进行有效的掺杂从而具有电化学活性.最后用HMSs-PANI来负载抗癌药物盐酸阿霉素(DOX),其展现了良好的酸性pH可控释放行为,在pH=7.4时,22 h后仅有15%的药物累计释放量.在pH=5的条件下,22 h后累计释放量达到44%,而在pH=4条件且同样时间之下,释放量为60%.总之,合成的HMSs-PANI酸响应药物控制释放体系在药物传输领域具有潜在应用.     

Silk Fibroin-Coated Liposomes as Biomimetic Nanocarrier for Long-Term Release Delivery System in Cancer Therapy

Despite much progress in cancer therapy, conventional chemotherapy can cause poor biodistribution and adverse side-effects on healthy cells. Currently, various strategies are being developed for an effective chemotherapy delivery system. Silk fibroin (SF) is a natural protein used in a wide range of biomedical applications including cancer therapy due to its biocompatibility, biodegradability, and unique mechanical properties. In this study, SF-coated liposomes (SF-LPs) were prepared as a biomimetic drug carrier. Physicochemical properties of SF-LPs were characterized by Fourier-transform infrared spectroscopy (FTIR), dynamic light scattering, zeta potential measurement, and transmission electron microscopy (TEM). In vitro release of SF-LPs loaded with doxorubicin (DOX-SF-LPs) was evaluated over 21 days. Anticancer activity of DOX-SF-LPs was determined against MCF-7 and MDA-MB231 cells using the MTT assay. SF-LPs containing 1% SF exhibited favorable characteristics as a drug carrier. SF coating modified the kinetics of drug release and reduced the cytotoxic effect against L929 fibroblasts as compared to the uncoated liposomes containing cationic lipid. DOX-SF-LPs showed anticancer activity against breast cancer cells after 48 h or 72 h at 20 μM of DOX. This approach provides a potential platform of long-term release that combines biocompatible SF and phospholipids for cancer therapy, achieving efficient drug delivery and reducing side-effects.     

Bioresponsive Hyaluronic Acid‐Capped Mesoporous Silica Nanoparticles for Targeted Drug Delivery

In this paper, we present a facile strategy to synthesize hyaluronic acid (HA) conjugated mesoporous silica nanoparticles (MSP) for targeted enzyme responsive drug delivery, in which the anchored HA polysaccharides not only act as capping agents but also as targeting ligands without the need of additional modification. The nanoconjugates possess many attractive features including chemical simplicity, high colloidal stability, good biocompatibility, cell‐targeting ability, and precise cargo release, making them promising agents for biomedical applications. As a proof‐of‐concept demonstration, the nanoconjugates are shown to release cargoes from the interior pores of MSPs upon HA degradation in response to hyaluronidase‐1 (Hyal‐1). Moreover, after receptor‐mediated endocytosis into cancer cells, the anchored HA was degraded into small fragments, facilitating the release of drugs to kill the cancer cells. Overall, we envision that this system might open the door to a new generation of carrier system for site‐selective, controlled‐release delivery of anticancer drugs.     

Periodic Mesoporous Organosilica Nanoparticles with Controlled Morphologies and High Drug/Dye Loadings for Multicargo Delivery in Cancer Cells

Despite the worldwide interest generated by periodic mesoporous organosilica (PMO) bulk materials, the design of PMO nanomaterials with controlled morphology remains largely unexplored and their properties unknown. In this work, we describe the first study of PMO nanoparticles (NPs) based on meta‐phenylene bridges, and we conducted a comparative structure–property relationship investigation with para‐phenylene‐bridged PMO NPs. Our findings indicate that the change of the isomer drastically affects the structure, morphology, size, porosity and thermal stability of PMO materials. We observed a much higher porosity and thermal stability of the para‐based PMO which was likely due to a higher molecular periodicity. Additionally, the para isomer could generate multipodal NPs at very low stirring speed and upon this discovery we designed a phenylene–ethylene bridged PMO with a controlled Janus morphology. Unprecedentedly high payloads could be obtained from 40 to 110 wt % regardless of the organic bridge of PMOs. Finally, we demonstrate for the first time the co‐delivery of two cargos by PMO NPs. Importantly, the cargo stability in PMOs did not require the capping of the pores, unlike pure silica, and the delivery could be autonomously triggered in cancer cells by acidic pH with nearly 70 % cell killing.     

Chitosan‐Capped Mesoporous Silica Nanoparticles as pH‐Responsive Nanocarriers for Controlled Drug Release

Herein, we present a straightforward synthesis of pH‐responsive chitosan‐capped mesoporous silica nanoparticles (MSNs). These MCM‐41‐type MSNs could be used as nanocapsules to accommodate guest molecules. Subsequently, (3‐glycidyloxypropyl)trimethoxysilane was grafted onto the surface of the MSNs, which served as a bridge to link between MSNs and chitosan, which is ubiquitous in nature and commercially available. Owing to the pH‐responsive and biocompatible features of chitosan, the loading and release of an anti‐cancer drug, doxorubicin hydrochloride, were carried out in vitro, in which the composite chitosan‐capped MSNs (CS‐MSNs) showed excellent environmental response. As the pH value of the media decreased, the degree of drug release correspondingly increased. Moreover, thanks to the perfect biocompatibility of chitosan, the CS‐MSNs exhibited lower cytotoxicity than that of the naked MSNs in an MTT assay. In addition, the in vitro kill potency against MCF‐7 breast‐cancer cells was enhanced over time, as well as with increasing concentration of the drug‐loaded CS‐MSNs. These results indicate that CS‐MSNs are promising candidates for pH‐responsive drug delivery in cancer therapy.     

Differential Effects of Polymer‐Surface Decoration on Drug Delivery,Cellular Retention,and Action Mechanisms of Functionalized Mesoporous Silica Nanoparticles

Polymer‐surface decoration has been found to be an effective strategy to enhance the biological activities of nanomedicine. Herein, three different types of polymers with a cancer‐targeting ligand Arg‐Gly‐Asp peptide (RGD) have been used to decorate mesoporous silica nanoparticles (MSNs) and the functionalized nanosystems were used as drug carriers of oxaliplatin (OXA). The results showed that polymer‐surface decoration of the MSNs nanosystem by poly(ethylene glycol) (PEG) and polyethyleneimine (PEI) significantly enhanced the anticancer efficacy of OXA, which was much higher than that of chitosan (CTS). This effect was closely related to the enhancement of the cellular uptake and cellular drug retention. Moreover, PEI@MSNs‐OXA possessed excellent advantages in penetrating ability and inhibitory effects on SW480 spheroids that were used to simulate the in vivo tumor environments. Therefore, this study provides useful information for the rational design of a cancer‐targeted MSNs nanosystem with polymer‐surface decoration.     

Chemical Design of Nuclear‐Targeting Mesoporous Silica Nanoparticles for Intra‐nuclear Drug Delivery

Targeted drug delivery has been widely explored for efficient tumor therapy with desired efficacy but minimized side effects. It is widely known that large numbers of DNA‐toxins, such as doxorubicin, genes, reactive oxygen species, serving as therapeutic agents, can result in maximized therapeutic effects via the interaction directly with DNA helix. So after cellular uptake, these agents should be further delivered into cell nuclei to play their essential roles in damaging the DNA helix in cancer cells. Here, we demonstrate the first paradigm established in our laboratory in developing nuclear‐targeted drug delivery systems (DDSs) based on MSNs for enhanced therapeutic efficiency in the hope of speeding their translation into the clinics. Firstly, nuclear‐targeting DDSs based on MSNs, capable of intranuclear accumulation and drug release therein, were designed and constructed for the first time, resulting in much enhanced anticancer effects both in vitro and in vivo. Such an MSNs‐based and nuclear‐targeted drug/agent delivery strategy was further applied to overcome multidrug resistance (MDR) of malignant tumors, intra‐nuclearly deliver therapeutic genes, photosensitizers, radio‐enhancement agents and photothermal agents to realize efficient gene therapy, photodynamic therapy, radiation therapy and photothermal therapy, respectively.